A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Publisher： Karger

E-ISSN： 1421-9913|44|4|236-241

ISSN： 0014-3022

Source： European Neurology, Vol.44, Iss.4, 2000-11, pp. : 236-241

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer’s Disease: Results from a 52-Week, Open-Label, Multicenter, Extension Study in Japan

By  

Dementia and Geriatric Cognitive Disorders, Vol. 27, Iss. 3, 2009-02 ,pp. : 232-239

Karger

Access to resources Recommend Favorite

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-06 ,pp. : 163-179

Karger

Access to resources Recommend Favorite

A 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 19, Iss. 1, 2004-12 ,pp. : 51-56

Karger

Access to resources Recommend Favorite

A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 5, Iss. 3, 2015-09 ,pp. : 361-374

Karger

Access to resources Recommend Favorite

Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 33, Iss. 5, 2012-07 ,pp. : 341-353

Karger

Access to resources Recommend Favorite